title: Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
abstract: OBJECTIVE
  To evaluate the effect of oral treosulfan in patients with platinum-resistant ovarian cancer.
  
  
  METHODS
  A phase II trial of oral treosulfan 500 mg per day in 30 females with platinum resistant ovarian cancer. All patients had measurable or evaluable disease.
  
  
  RESULTS
  The treatment was well tolerated. One patient (3%) achieved a partial response lasting 12+ months. Seven patients had stable disease for 5.3 months (median) range 4.4-7.5 months. Median time to progression was 11.5 weeks (95% C.L. 11-12 weeks). Median survival was 31 weeks (95% C.L. 30-35 weeks).
  
  
  CONCLUSIONS
  Oral treosulfan in the present schedule is not recommended in platinum resistant ovarian cancer.
authors.affiliation: Department of Oncology, Herning Centralsygehus, Denmark.
authors.forename: N
authors.initials: N
authors.lastname: Keldsen
authors.forename: E L
authors.initials: EL
authors.lastname: Madsen
authors.forename: H
authors.initials: H
authors.lastname: Havsteen
authors.forename: C
authors.initials: C
authors.lastname: Kamby
authors.forename: L
authors.initials: L
authors.lastname: Laursen
authors.forename: E
authors.initials: E
authors.lastname: Sandberg
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000494:pharmacology*; D003718:Denmark; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; C018404:treosulfan; D002066:Busulfan; D002945:Cisplatin